advertising
-
1
Scher RK: Onychomycosis: a significant medical disorder. .J Am Acad Dermatol 35 (3 pt 2)::S2. ,1996. .
-
2
Drake LA, Scher RK, Smith EB, et al: Effect of onychomycosis on quality of life. .J Am Acad Dermatol 38 (5 pt 1)::702. ,1998. .
-
3
Lubeck DP, Patrick DL, McNulty P, et al: Quality of life of persons with onychomycosis. .Qual Life Res 2::341. ,1993. .
-
4
Arenas R, Dominguez-Cherit J, Fernandez LM: Open randomized comparison of itraconazole versus terbinafine in onychomycosis. .Int J Dermatol 34::138. ,1996. .
-
5
Bräutigam M, Nolting S, Schopf RE, et al: Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. .BMJ 311::919. ,1995. .
-
6
Arikian SR, Einarson TR, Kobelt-Nguyen G, et al: A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. .Br J Dermatol 130 (suppl 43)::35. ,1994. .
-
7
Marchetti A, Piech CT, McGhan WF, et al: Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. .Clin Ther 18::757. ,1996. .
-
8
Stier DM, Henke C, Schein J, et al: Cost of treatment for onychomycosis: data from a 9-month observational study. .Pharmacoeconomics 19::267. ,2001. .
-
9
Schein JR, Gause D, Stier DM, et al: Onychomycosis: baseline results of an observational study. .JAPMA 87::512. ,1997. .
-
10
Stewart AL, Ware JE, Jr (eds): Measuring Functioning and Well-Being: The Medical Outcomes Study Approach, Duke University Press, Durham NC, 1992..
-
11
Ware JE, Snow KK, Kosinki M, et al: SF-36 Health Survey: Manual and Interpretation Guide, The Health Institute, New England Medical Center, Boston, 1993..
-
12
Lubeck DP, Gause D, Schein JR, et al: A health-related quality of life measure for use in patients with onychomycosis: a validation study. .Qual Life Res 8::121. ,1999. .
-
13
Barnett DB: Assessment of quality of life. .Am J Cardiol 67::41C. ,1991. .
-
14
Drake L: Quality of life issues for patients with fungal nail infections. .AIDS Patient Care 9 (suppl 1)::15. ,1995. .
-
15
Chiritescu MM, Chiritescu ME, Scher RK: Newer systemic antifungal drugs for the treatment of onychomycosis. .Clin Podiatr Med Surg 13::741. ,1996. .
-
16
Faergemann J, Zehender H, Boukhabza A, et al: A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication [letter]. .Acta Derm Venereol 77::74. ,1996. .
-
17
van der Schroeff JG, Cirkel PKS, Crijns MB, et al: A randomized treatment duration-finding study of terbinafine in onychomycosis. .Br J Dermatol 126 (suppl)::36. ,1992. .
-
18
Svejgaard EL, Brandrup F, Kragballe K, et al: Oral terbinafine in toenail dermatophytosis: a double-blind, placebo-controlled multicenter study with 12 months’ follow-up. .Acta Derm Venereol 77::66. ,1997. .
-
19
Elewski BE: Diagnostic techniques for confirming onychomycosis. .J Am Acad Dermatol 35 (3 pt 2)::S6. 1996. .
Patient Satisfaction with Oral versus Nonoral Therapeutic Approaches in Onychomycosis
Search for other papers by David M. Stier in
Current site
Google Scholar
PubMed
Search for other papers by Douglas Gause in
Current site
Google Scholar
PubMed
Search for other papers by Warren S. Joseph in
Current site
Google Scholar
PubMed
Search for other papers by Jeffrey R. Schein in
Current site
Google Scholar
PubMed
Search for other papers by Jeanette M. Broering in
Current site
Google Scholar
PubMed
Search for other papers by Karen L. Warolin in
Current site
Google Scholar
PubMed
Search for other papers by Joseph J. Doyle in
Current site
Google Scholar
PubMed
The follow-up results of a 9-month observational study of 150 onychomycosis patients treated with a variety of mechanical, topical, and oral therapies by podiatric physicians and dermatologists are presented. Changes from baseline in toenail condition and patient satisfaction were assessed at 4- and 9-month follow-up. At 9 months, patients who had received oral therapy reported significantly fewer onychomycosis-related problems in social situations, including embarrassment or self-consciousness about the appearance of nails, avoidance of contact by others, being perceived as unclean or untidy, and the desire to keep their nails concealed. Patient-reported satisfaction with the treatment program was significantly higher for those receiving oral therapy than for those receiving nonoral therapy. (J Am Podiatr Med Assoc 91(10): 521-527, 2001)
This study was underwritten by Novartis Pharmaceuticals Corp, East Hanover, NJ.
advertising
